Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.110
-0.040 (-3.48%)
At close: Aug 28, 2026, 4:00 PM EDT
1.116
+0.006 (0.54%)
After-hours: Aug 28, 2026, 5:46 PM EDT
Pliant Therapeutics Employees
Pliant Therapeutics had 49 employees as of December 31, 2025. The number of employees decreased by 122 or -71.35% compared to the previous year.
Employees
49
Change (1Y)
-122
Growth (1Y)
-71.35%
Revenue / Employee
n/a
Profits / Employee
-$1,883,449
Market Cap
68.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 49 | -122 | -71.35% |
| Dec 31, 2024 | 171 | 13 | 8.23% |
| Sep 30, 2024 | 166 | 7 | 4.40% |
| Jun 30, 2024 | 166 | 11 | 7.10% |
| Mar 31, 2024 | 158 | 22 | 16.18% |
| Dec 31, 2023 | 158 | 34 | 27.42% |
| Sep 30, 2023 | 159 | 45 | 39.47% |
| Jun 30, 2023 | 155 | 45 | 40.91% |
| Mar 31, 2023 | 136 | 35 | 34.65% |
| Dec 31, 2022 | 124 | 33 | 36.26% |
| Sep 30, 2022 | 114 | 24 | 26.67% |
| Jun 30, 2022 | 110 | 20 | 22.22% |
| Mar 31, 2022 | 101 | 11 | 12.22% |
| Dec 31, 2021 | 91 | 13 | 16.67% |
| Sep 30, 2021 | 90 | 20 | 28.57% |
| Jun 30, 2021 | 90 | 23 | 34.33% |
| Mar 31, 2021 | 90 | 28 | 45.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 214 |
| XBiotech | 87 |
| MindWalk Holdings | 77 |
| PMV Pharmaceuticals | 54 |
| eXoZymes | 32 |
| Cardiff Oncology | 31 |
| Spero Therapeutics | 25 |
| INmune Bio | 21 |
PLRX News
- 11 days ago - Pliant Therapeutics receives Fast Track designation from FDA for PLN-101095 - TheFly
- 11 days ago - Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors - GlobeNewsWire
- 12 days ago - Pliant Therapeutics reports Q2 EPS (36c), consensus (34c) - TheFly
- 18 days ago - Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 18 days ago - Pliant Therapeutics Quarterly report: Q2 2026 - Filings
- 18 days ago - Pliant Therapeutics Earnings release: Q2 2026 - Filings
- 6 weeks ago - Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D. - GlobeNewsWire
- 3 months ago - Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - GlobeNewsWire